• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Government shutdown: What of FDA’s October meetings?

Government shutdown: What of FDA’s October meetings?

October 7, 2013 By Arezu Sarvestani

Government shutdown: What of FDA's October meetings?

With the ongoing government shutdown, the FDA is likely to have increasing trouble meeting its commitments, according to medical device industry analysts at GlobalData. That spells trouble for companies such that are scheduled for FDA panel meetings in coming weeks, and it could "spook" investors, GlobalData warned.

The FDA’s Circulatory System Devices Panel is scheduled to meet this week to discuss expanded indication for a fleet of Medtronic (NYSE:MDT) cardiac implants and to consider CardioMEMs’ Champion HF patient monitoring system. That meeting is still on the docket, according to the FDA’s website, but others have been taken off the books.

Already sacrificed is the October 7 public workshop run by the FDA’s Center for Biologics Evaluation & Research, the FDA said. No additional details or postponement dates were provided.

The federal watchdog agency lost about 45% of its staff to furloughs, amounting to some 40,500 workers, according to a memo from the Dept. of Health & Human Services. The agency is also no longer able accept new applications for medical devices or drugs, as it’s not able to collect the user fees companies usually pay for review of new products, according to an FDA memo.

"FDA would continue limited activities related to its user fee funded programs including the activities in the Center for Tobacco Products," according to the notice. "FDA would also continue select vital activities including maintaining critical consumer protection to handle emergencies, high-risk recalls, civil and criminal investigations, import entry review, and other critical public health issues."

That leaves routine facility inspections, import monitoring, notification programs and other duties by the wayside, but certain medical device and drug responsibilities remain funded by user fees that the FDA collected prior to the shutdown.

"Only ‘life-and-death’ work is expected to persist, although the DHHS has noted that the FDA will attempt to continue limited activities related to user fee-funded programs, such as medical device approvals," according to medtech analyst Robert Littlefield of GlobalData. "GlobalData expects the shutdown to appreciably limit agency panel discussions as well as result in the indefinite postponement of meetings, which could muddle commercial launches and spook device company investors."

It’s also likely that the FDA’s guidance-release efforts would be hampered, perhaps even halted entirely, until things get running again on Capitol Hill, Littlefield wrote.

Filed Under: Food & Drug Administration (FDA), News Well, Regulatory/Compliance Tagged With: User fees

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy